Tudor Investment Corp ET AL Trims Holdings in Theravance Biopharma, Inc. $TBPH

Tudor Investment Corp ET AL decreased its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 74.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 51,048 shares of the biopharmaceutical company’s stock after selling 145,515 shares during the period. Tudor Investment Corp ET AL’s holdings in Theravance Biopharma were worth $745,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Theravance Biopharma in the third quarter worth $10,611,000. Assenagon Asset Management S.A. lifted its stake in shares of Theravance Biopharma by 1,629.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after buying an additional 390,735 shares in the last quarter. Hillsdale Investment Management Inc. purchased a new position in shares of Theravance Biopharma during the 3rd quarter valued at $4,536,000. Two Sigma Investments LP boosted its holdings in Theravance Biopharma by 1,199.9% in the 3rd quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock worth $3,377,000 after buying an additional 213,480 shares during the period. Finally, Algert Global LLC bought a new position in Theravance Biopharma in the 3rd quarter worth $2,916,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the transaction, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 6.90% of the stock is owned by corporate insiders.

Theravance Biopharma Stock Up 6.4%

Shares of Theravance Biopharma stock opened at $16.23 on Wednesday. Theravance Biopharma, Inc. has a twelve month low of $7.90 and a twelve month high of $21.03. The business has a 50-day moving average price of $17.32 and a 200-day moving average price of $16.95. The firm has a market cap of $835.68 million, a price-to-earnings ratio of 8.00 and a beta of 0.17.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TBPH shares. Zacks Research raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 19th. TD Cowen increased their target price on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, March 23rd. Wall Street Zen raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Sunday. BTIG Research reissued a “buy” rating and issued a $21.00 price target on shares of Theravance Biopharma in a report on Friday, March 20th. Finally, Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $21.33.

Theravance Biopharma Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.